Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q2 2026 › vs Q2 2025
Tonix Pharmaceuticals Holding (TNXP) Q2 2026 vs Q2 2025 (year over year)
Tonix Pharmaceuticals Holding's revenue rose $11.5M (+578%) from $2.0M in Q2 2025 to $13.5M in Q2 2026. The biggest changes: Zembrace Symtouch +$426K (+27%); Tosymra +$166K (+39%).
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Zembrace Symtouch | $2.0M | $1.6M | $426K | +27% |
| Tosymra | $594K | $428K | $166K | +39% |
| Revenue | $13.5M | $2.0M | $11.5M | +578% |
| Other income, net | $2.0M | $24K | $2.0M | 83× |
| Net loss | $40.6M | $28.3M | $12.3M | +43% |
| Costs & expenses | $56.1M | $30.3M | $25.8M | +85% |
| Operating costs | $56.1M | $30.3M | $25.8M | +85% |
| Cost of revenue | $703K | $3.3M | −$2.6M | -79% |
| Research & development | $19.4M | $10.8M | $8.6M | +79% |
| SG&A | $36.0M | $16.2M | $19.8M | +122% |
| Operating cash sources | $45.1M | $16.7M | $28.4M | +170% |
| Depreciation & amortization | $619K | $483K | $136K | +28% |
| Share-based compensation | $2.3M | $1.4M | $833K | +59% |
| Cash used in operations | $42.2M | $14.8M | $27.4M | +185% |
| Net loss absorbed | $40.6M | $28.3M | $12.3M | +43% |
| Working capital & other | $4.6M | −$11.5M | $16.1M | — |
Questions
How much did Tonix Pharmaceuticals Holding's revenue grow year over year in Q2 2026?
Tonix Pharmaceuticals Holding's revenue rose $11.5M (+578%) from $2.0M in Q2 2025 to $13.5M in Q2 2026.
What drove Tonix Pharmaceuticals Holding's revenue change in Q2 2026?
Zembrace Symtouch +$426K (+27%); Tosymra +$166K (+39%).